Go Pro
→ This under $7 stock could be. (From Freedom Financial) (Ad)tc pixel Free FBT Stock Alerts

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (FBT) Competitors

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation logo
GBX 2,319.25 0.00 (0.00%)
As of 07/29/2026
Compare

FBT vs. SOPH, PRSM, KAPE, TRST, and KNOS

Should you buy First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? MarketBeat compares First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Sophos Group plc (SOPH.L) (SOPH), Blue Prism Group (PRSM), Kape Technologies (KAPE), Trustpilot Group (TRST), and Kainos Group (KNOS). These companies are all part of the "software - application" industry.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Sophos Group plc (SOPH.L)?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Sophos Group plc (SOPH.L) (LON:SOPH) are both computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Sophos Group plc (SOPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Sophos Group plc (SOPH.L)£726.90M0.00N/A£1.70N/A

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Sophos Group plc (SOPH.L)'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Sophos Group plc (SOPH.L) Neutral

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Sophos Group plc (SOPH.L) N/A N/A N/A

Summary

Sophos Group plc (SOPH.L) beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 3 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Blue Prism Group?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Blue Prism Group (LON:PRSM) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Blue Prism Group'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Blue Prism Group Neutral

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Blue Prism Group N/A N/A N/A

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Blue Prism Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Blue Prism Group£167.30M0.00N/A-£53.80N/A

Summary

Blue Prism Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 2 of the 3 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kape Technologies?

Kape Technologies (LON:KAPE) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Kape Technologies has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, suggesting that its share price is 51% less volatile than the broader market.

Kape Technologies has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kape Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kape Technologies£623.48M0.00£70.92M£0.15N/A
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A

In the previous week, Kape Technologies had 1 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 1 mentions for Kape Technologies and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Kape Technologies' average media sentiment score of 0.00 equaled First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation'saverage media sentiment score.

Company Overall Sentiment
Kape Technologies Neutral
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral

Kape Technologies has a net margin of 11.37% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kape Technologies' return on equity of 6.97% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
Kape Technologies11.37% 6.97% 3.47%
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation N/A N/A N/A

11.4% of Kape Technologies shares are owned by institutional investors. 81.1% of Kape Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Kape Technologies beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 10 of the 10 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Trustpilot Group?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Trustpilot Group (LON:TRST) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Trustpilot Group has a net margin of 2.97% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Trustpilot Group's return on equity of 64.11% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Trustpilot Group 2.97%64.11%1.45%

Trustpilot Group has a consensus target price of GBX 351.25, indicating a potential upside of 29.13%. Given Trustpilot Group's stronger consensus rating and higher probable upside, analysts clearly believe Trustpilot Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Trustpilot Group
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

42.7% of Trustpilot Group shares are held by institutional investors. 13.5% of Trustpilot Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.00 equaled Trustpilot Group'saverage media sentiment score.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Trustpilot Group Neutral

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Trustpilot Group has a beta of 0.507, suggesting that its share price is 49% less volatile than the broader market.

Trustpilot Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Trustpilot Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Trustpilot Group£261.05M4.02£20.08M£1.80151.11

Summary

Trustpilot Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 12 of the 12 factors compared between the two stocks.

How does First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation compare to Kainos Group?

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Kainos Group (LON:KNOS) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Kainos Group has a net margin of 9.86% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 41.45% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.

Company Net Margins Return on Equity Return on Assets
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/A N/A N/A
Kainos Group 9.86%41.45%14.45%

36.8% of Kainos Group shares are owned by institutional investors. 19.7% of Kainos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationN/AN/AN/A-£1.10N/A
Kainos Group£431.10M2.40£48.81M£35.1025.59

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation has a beta of 0.4890005, meaning that its share price is 51% less volatile than the broader market. Comparatively, Kainos Group has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Kainos Group has a consensus target price of GBX 1,173.40, suggesting a potential upside of 30.64%. Given Kainos Group's stronger consensus rating and higher possible upside, analysts plainly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kainos Group
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Kainos Group had 1 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 1 mentions for Kainos Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. Kainos Group's average media sentiment score of 0.37 beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's score of 0.00 indicating that Kainos Group is being referred to more favorably in the news media.

Company Overall Sentiment
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Neutral
Kainos Group Neutral

Summary

Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 14 of the 14 factors compared between the two stocks.

Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically

Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBT vs. The Competition

Export
MetricFirst Trust NYSE Arca Biotechnology UCITS ETF Class A USD AccumulationSoftware IndustryComputer SectorLON Exchange
Market Cap£951.39M£5.29B£37.30B£2.83B
Dividend YieldN/A4.05%3.15%6.15%
P/E Ratio-2,108.4127.4475.93367.89
Price / SalesN/A243.76595.2784,333.40
Price / Cash3.5417.3542.8427.89
Price / BookN/A4.348.337.03
Net IncomeN/A£22.26M£1.08B£5.89B
7 Day Performance1.73%1.92%0.04%0.58%
1 Month Performance0.98%0.46%-2.64%0.72%
1 Year Performance49.57%-12.69%134.56%67.26%

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBT
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
N/AGBX 2,319.25
flat		N/A+50.0%£951.39MN/AN/A20
SOPH
Sophos Group plc (SOPH.L)
N/AN/AN/AN/A£2.99B£726.90M341.41520
PRSM
Blue Prism Group
N/AN/AN/AN/A£1.24B£167.30MN/A1,025
KAPE
Kape Technologies
N/AN/AN/AN/A£1.22B£623.48M1,900.00850
TRST
Trustpilot Group
N/AGBX 279.80
+1.0%		GBX 351.25
+25.5%		+9.3%£1.08B£261.05M155.44820

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FBT) was last updated on 7/30/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The oil crisis is spreading faster than you think
Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...
Golden Portfolio | Sponsoredtc pixel
While the world panicked, these investors got paid
Since Feb 28, the S&P 500 has slid 4.1% amid war fears and oil spikes to $117. Patriot Income Plan (P.I.P.) pa...
Freedom Financial | Sponsoredtc pixel